Where does Mineralys Therapeutics, Inc.'s cash flow data come from?

Every line is extracted from Mineralys Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

	Q1 '26	Q4 '25	Q3 '25	Q2 '25	Q1 '25
Net income	-$39.34M+6.8%	-$32.23M+34.1%	-$36.93M+34.5%	-$43.27M-5.5%	-$42.21M-34.0%
Depreciation and amortization	$6K-60.0%	$13K-13.3%	$15K+36.4%	$16K+77.8%	$15K+87.5%
Stock-based compensation	$6.55M+79.6%	$5.29M+68.6%	$5.84M+86.1%	$4.55M+58.5%	$3.65M+66.4%
Change in accounts payable	-$402K+74.0%	——	$1.03M-65.2%	$9.07M-4.2%	-$1.55M-118%
Change in other assets	$1.95M-55.7%	-$1.57M—	-$3.56M-30.4%	-$1.74M-47.5%	$4.4M+206%
Change in accrued investment income	-$289K-456%	$181K+285%	-$10K+56.5%	$47K+126%	-$52K+56.3%
Net cash from operating activities	-$39.47M+13.2%	-$37.89M+43.3%	-$28.87M+42.5%	-$30.17M-0.1%	-$45.49M-138%
Proceeds from maturities/sales of investments	$302.5M+764%	$165M+11.9%	$150M+8.3%	$75M-44.4%	$35M-48.1%
Purchases of fixed maturity securities	$347.44M+172%	$268.47M+320%	$300.51M+411%	$117.88M-7.4%	$127.88M+3.6%
Net cash from investing activities	-$44.94M+51.6%	-$103.49M-224%	-$150.51M-289%	-$42.88M-654%	-$92.88M-66.0%
Proceeds from issuance of common stock	$4.06M-97.9%	$4.96M+9,085%	$6.62M+16,460%	——	$189.17M—
Net cash from financing activities	$24.27M-87.2%	$96.7M+107,346%	$295.19M—	$9.83M—	$189.28M+62.9%
Net increase (decrease) in cash	-$60.14M-218%	——	$115.81M+294%	-$63.22M—	$50.92M+23.8%
Accretion (Amortization) of Discounts and Premiums, Investments	$4.63M+342%	$4.21M+215%	$2.4M-11.7%	$2.23M-21.7%	$1.05M-58.3%
Increase (Decrease) in Accrued Interest Receivable, Net	-$289K-456%	$181K+285%	-$10K+56.5%	$47K+126%	-$52K+56.3%
Increase (Decrease) in Prepaid Expense and Other Assets	$1.95M-55.7%	-$1.57M—	-$3.56M-30.4%	-$1.74M-47.5%	$4.4M+206%
Payments to Acquire Held-to-Maturity Securities	$347.44M+172%	$268.47M+320%	$300.51M+411%	$117.88M-7.4%	$127.88M+3.6%
Payments Of Stock Issuance Costs	$1K-90.0%	$305K+549%	$29K-29.3%	$47K-83.5%	$10K-84.1%
Public offering and shelf offering costs included in accounts payable and accrued liabilities	$7K-97.6%	——	$304K+824%	——	$289K-10.0%
Free cash flow	——	-$37.9M+43.3%	-$28.87M+42.5%	-$30.17M-0.1%	-$45.49M-137%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Where does Mineralys Therapeutics, Inc.'s cash flow data come from?: Every line is extracted from Mineralys Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.